Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients

Multiple myeloma survival has significantly improved in recent years, due to novel agents that are available for treatment. The anti-CD38 monoclonal antibody Daratumumab is particularly efficient for patients with relapse/refractory disease, and many studies have shown its unprecedented efficacy als...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Main Authors: Gozzetti, Alessandro, Bacchiarri, Francesca, Sammartano, Vincenzo, Defina, Marzia, Sicuranza, Anna, Mecacci, Bianca, Zappone, Elisabetta, Cencini, Emanuele, Fabbri, Alberto, Raspadori, Donatella, Bocchia, Monica
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2020
Assuntos:
Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7783633/
https://ncbi.nlm.nih.gov/pubmed/33415072
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.570187
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares